Iva Gunnarsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Iva Gunnarsson has a total of 321 co-authors. Here are the top co-authors by number of shared publications:
- Elisabet Svenungsson
Karolinska University Hospital Department of Rheumatology Stockholm
10 shared publications - Christopher Sjöwall
Linköping University
8 shared publications - Dag Leonard
Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden
5 shared publications - Susanne Pettersson
Karolinska University Hospital Department of Rheumatology Stockholm
5 shared publications - Andreas Jönsen
Department of Clinical Sciences Lund Rheumatology Lund University Skåne University Hospital Lund Sweden
4 shared publications - Ingrid E. Lundberg
Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet Stockholm Sweden
4 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
Health-related quality of life in relation to fatigue, depression, anxiety, and disease manifestations in systemic lupus erythematosus and vasculitis
Objectives: We explored health-related quality of life (HRQoL) in relation to fatigue, depression, anxiety, and disease characteristics in people with ANCA-associated vasculitis (AAV) and Systemic Lupus Erythematosus (SLE). Methods: In this cross-sectional study, patient-reported outcome measures included HRQoL (EQ-5D-3L), fatigue (Multidimensional Assessment of Fatigue), and anxiety and depression (Hospital Anxiety and Depression Scale). Physicians assessed disease activity and characteristics. Group comparisons used chi-square and Mann–Whitney U tests. Multivariable linear regression models identified determinants of HRQoL. Results: We included 481 individuals with SLE, 256 with AAV, and 125 controls. Individuals with AAV and SLE experienced reduced HRQoL, greater fatigue, and higher levels of anxiety and depression compared to controls, but no differences were found between SLE and AAV. In combined SLE/AAV analyses, active organ involvement (skin, lungs, kidneys), was associated with lower HRQoL and more fatigue. In linear regression, including physical, social, and disease-specific aspects (Model A), active disease and older age were associated with lower HRQoL, while being male and cohabitation were associated with higher HRQoL. The adjusted R² value indicated that Model A explained 12.1% of the variance in HRQoL. After adding psychological aspects, fatigue, depression, and anxiety (Model B), the adjusted R² value indicated that the model explained 35.9% of the variance, increasing the proportion of HRQoL variance explained. Conclusion: Across SLE and AAV diagnoses, active organ involvement in skin, lungs and kidneys was associated with lower HRQoL and more fatigue. Furthermore, combining disease characteristics with psychological aspects increased the explanatory determinants of HRQoL in both diseases.
- 10 November 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
Open AccessHealth-related quality of life in relation to fatigue, depression, anxiety, and disease manifestations in systemic lupus erythematosus and vasculitis
Objectives: We explored health-related quality of life (HRQoL) in relation to fatigue, depression, anxiety, and disease characteristics in people with ANCA-associated vasculitis (AAV) and Systemic Lupus Erythematosus (SLE). Methods: In this cross-sectional study, patient-reported outcome measures included HRQoL (EQ-5D-3L), fatigue (Multidimensional Assessment of Fatigue), and anxiety and depression (Hospital Anxiety and Depression Scale). Physicians assessed disease activity and characteristics. Group comparisons used chi-square and Mann–Whitney U tests. Multivariable linear regression models identified determinants of HRQoL. Results: We included 481 individuals with SLE, 256 with AAV, and 125 controls. Individuals with AAV and SLE experienced reduced HRQoL, greater fatigue, and higher levels of anxiety and depression compared to controls, but no differences were found between SLE and AAV. In combined SLE/AAV analyses, active organ involvement (skin, lungs, kidneys), was associated with lower HRQoL and more fatigue. In linear regression, including physical, social, and disease-specific aspects (Model A), active disease and older age were associated with lower HRQoL, while being male and cohabitation were associated with higher HRQoL. The adjusted R² value indicated that Model A explained 12.1% of the variance in HRQoL. After adding psychological aspects, fatigue, depression, and anxiety (Model B), the adjusted R² value indicated that the model explained 35.9% of the variance, increasing the proportion of HRQoL variance explained. Conclusion: Across SLE and AAV diagnoses, active organ involvement in skin, lungs and kidneys was associated with lower HRQoL and more fatigue. Furthermore, combining disease characteristics with psychological aspects increased the explanatory determinants of HRQoL in both diseases.
- Open Access
- 3 November 2026
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 104 (5) , e70164
Quantification of Anti‐Ro52, Anti‐Ro60 and Anti‐La Autoantibodies at High Sample Dilution and Their Predictive Value for Congenital Heart Block
Maternal anti‐Ro/La antibodies confer a risk of congenital heart block (CHB), but current methods for predicting risk relying on the presence or absence of these autoantibodies perform poorly. To identify more accurate biomarkers of CHB risk, we investigated the association between maternal levels of autoantibodies and the risk of CHB. A total of 318 women positive for anti‐Ro/SSA autoantibodies were included. Autoantibody presence was obtained from health records for all, and ELISA was used to quantify levels of anti‐Ro52, anti‐Ro60, and anti‐La in a subset of 116 women with samples obtained during pregnancy, including 27 CHB‐affected pregnancies. Predictive models for CHB risk were developed using logistic regression and machine learning. Anti‐Ro/SSA positive women with anti‐Ro60 were more likely to have pregnancies with CHB ( p < 0.05). Levels of both anti‐Ro60 ( p < 0.001) and anti‐Ro52 ( p < 0.05) were significantly higher in CHB‐affected pregnancies and correlated ( r = 0.8, p < 0.0001), while levels of anti‐La did not differ between groups. Levels of anti‐Ro60 were identified as the strongest individual predictor of CHB, with a relative risk of 16.3 (95% CI 1.04–255.0, p < 0.001) for the top versus the bottom decile. In all tested combinations, models that included anti‐Ro60 levels outperformed models that did not. Models based on anti‐Ro60 levels alone reached an area under the curve (AUC) of 0.76 and an odds ratio (OR) per standard deviation increase of 2.8 (95% CI 1.6–5.3). These findings confirm a strong association between maternal anti‐Ro antibody levels and CHB risk in anti‐SSA‐positive pregnancy, highlighting anti‐Ro60 autoantibody levels as a valuable biomarker in risk stratification.
- 3 November 2026
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 104 (5) , e70164
Open AccessQuantification of Anti‐Ro52, Anti‐Ro60 and Anti‐La Autoantibodies at High Sample Dilution and Their Predictive Value for Congenital Heart Block
Maternal anti‐Ro/La antibodies confer a risk of congenital heart block (CHB), but current methods for predicting risk relying on the presence or absence of these autoantibodies perform poorly. To identify more accurate biomarkers of CHB risk, we investigated the association between maternal levels of autoantibodies and the risk of CHB. A total of 318 women positive for anti‐Ro/SSA autoantibodies were included. Autoantibody presence was obtained from health records for all, and ELISA was used to quantify levels of anti‐Ro52, anti‐Ro60, and anti‐La in a subset of 116 women with samples obtained during pregnancy, including 27 CHB‐affected pregnancies. Predictive models for CHB risk were developed using logistic regression and machine learning. Anti‐Ro/SSA positive women with anti‐Ro60 were more likely to have pregnancies with CHB ( p < 0.05). Levels of both anti‐Ro60 ( p < 0.001) and anti‐Ro52 ( p < 0.05) were significantly higher in CHB‐affected pregnancies and correlated ( r = 0.8, p < 0.0001), while levels of anti‐La did not differ between groups. Levels of anti‐Ro60 were identified as the strongest individual predictor of CHB, with a relative risk of 16.3 (95% CI 1.04–255.0, p < 0.001) for the top versus the bottom decile. In all tested combinations, models that included anti‐Ro60 levels outperformed models that did not. Models based on anti‐Ro60 levels alone reached an area under the curve (AUC) of 0.76 and an odds ratio (OR) per standard deviation increase of 2.8 (95% CI 1.6–5.3). These findings confirm a strong association between maternal anti‐Ro antibody levels and CHB risk in anti‐SSA‐positive pregnancy, highlighting anti‐Ro60 autoantibody levels as a valuable biomarker in risk stratification.
- Open Access
- 23 July 2026
- Published by Wiley in Journal of Internal Medicine
Placental malperfusion and angiogenesis‐related proteins are associated with small‐for‐gestational‐age in systemic lupus erythematosus
Background: Although systemic lupus erythematosus (SLE) pregnancy frequently results in small for gestational age (SGA) infants, the understanding of underlying mechanisms is limited. We aimed to identify specific histological patterns of placental injury in SGA in SLE and to explore whether an altered balance of angiogenesis‐related proteins precedes this outcome. Methods: We prospectively followed 83 SLE and 67 control pregnancies. Placental histological patterns were determined according to the Amsterdam consensus in 63 women with SLE (76%), of whom 10 developed SGA. Soluble fms‐like tyrosine kinase 1 (sFlt‐1) and placental growth factor (PlGF) in plasma were quantified using LEGENDplex in the first, second and third trimesters. Results: SLE patients remain at risk of having an SGA infant, and their placentas and infants had lower weight compared to controls. In placentas from women with SLE and SGA, maternal vascular malperfusion lesions were common (80% vs. 30% in controls; p = 0.010), but inflammatory lesions were not observed. Women with maternal vascular malperfusion gave birth to infants with lower birth weight compared to women without these lesions. The ratio of sFlt‐1:PlGF in the third trimester was elevated in women with SLE with an SGA infant. Conclusion: In a prospective cohort of well‐controlled SLE patients with low disease activity delivering mostly at term, SGA and small placentas remain common. The increased prevalence of placental malperfusion lesions together with an altered balance of pro‐ and anti‐angiogenic proteins suggests that the role of vascular and angiogenesis‐related factors should be further explored in relation to SGA in SLE pregnancy.
- 23 July 2026
- Published by Wiley in Journal of Internal Medicine
Open AccessPlacental malperfusion and angiogenesis‐related proteins are associated with small‐for‐gestational‐age in systemic lupus erythematosus
Background: Although systemic lupus erythematosus (SLE) pregnancy frequently results in small for gestational age (SGA) infants, the understanding of underlying mechanisms is limited. We aimed to identify specific histological patterns of placental injury in SGA in SLE and to explore whether an altered balance of angiogenesis‐related proteins precedes this outcome. Methods: We prospectively followed 83 SLE and 67 control pregnancies. Placental histological patterns were determined according to the Amsterdam consensus in 63 women with SLE (76%), of whom 10 developed SGA. Soluble fms‐like tyrosine kinase 1 (sFlt‐1) and placental growth factor (PlGF) in plasma were quantified using LEGENDplex in the first, second and third trimesters. Results: SLE patients remain at risk of having an SGA infant, and their placentas and infants had lower weight compared to controls. In placentas from women with SLE and SGA, maternal vascular malperfusion lesions were common (80% vs. 30% in controls; p = 0.010), but inflammatory lesions were not observed. Women with maternal vascular malperfusion gave birth to infants with lower birth weight compared to women without these lesions. The ratio of sFlt‐1:PlGF in the third trimester was elevated in women with SLE with an SGA infant. Conclusion: In a prospective cohort of well‐controlled SLE patients with low disease activity delivering mostly at term, SGA and small placentas remain common. The increased prevalence of placental malperfusion lesions together with an altered balance of pro‐ and anti‐angiogenic proteins suggests that the role of vascular and angiogenesis‐related factors should be further explored in relation to SGA in SLE pregnancy.
- Open Access
- 10 July 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (8)
Methylation and polygenic risk scores capture different features of Systemic Lupus Erythematosus
Objectives: The aetiopathogenesis of SLE encompasses genetic, environmental and epigenetic factors. We investigated associations between an SLE methylation risk score (MRS), HLA-DRB1*03:01, a non-HLA polygenic risk score (PRS), and clinical and immunological phenotypes. Methods: DNA methylation in whole blood from patients fulfilling ≥4 ACR-82 criteria and from controls was investigated using the Illumina HM450K array. The discovery cohort included 311 patients and 400 controls, and the replication cohort comprised 175 patients and 187 controls. Seventeen independent, top differentially methylated CpG sites (Δβ of ≥0.1) from case–control comparisons were used to calculate the MRS. Genotyping was performed using the Immunochip, and the PRS included 57 non-HLA SLE single-nucleotide variants. Clinical data were collected from patient charts, and serum IFN-α2 was measured using Simoa. Results: Higher MRS was strongly associated with serum IFN-α2 levels (P = 1.04 × 10−14). In both cohorts, higher MRS was associated with DLE, immunologic involvement, and anti-SSA/SSB/RNP/Sm autoantibodies (all P < 0.05), and with higher disease activity in the discovery cohort (P = 1.50 × 10−4). MRS was also elevated in patients with multiple autoantibodies (P < 1.0 × 10−15) and in HLA-DRB1*03:01 carriers (P < 1.0 × 10−3). In contrast, higher PRS was associated with nephritis, anti-dsDNA positivity, and lower prevalence of anti-SSB antibodies (all P < 0.05). No correlation was observed between the MRS and the PRS (P = 0.35). Conclusion: The MRS defines an IFN-high, HLA-DRB1*03:01-linked SLE subset with multiple autoantibodies, partly distinct from PRS-associated nephritis risk, highlighting potentially divergent pathogenic pathways. These findings underscore the value of integrating genetic and epigenetic data to better understand underlying disease mechanisms in SLE.
- 10 July 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (8)
Open AccessMethylation and polygenic risk scores capture different features of Systemic Lupus Erythematosus
Objectives: The aetiopathogenesis of SLE encompasses genetic, environmental and epigenetic factors. We investigated associations between an SLE methylation risk score (MRS), HLA-DRB1*03:01, a non-HLA polygenic risk score (PRS), and clinical and immunological phenotypes. Methods: DNA methylation in whole blood from patients fulfilling ≥4 ACR-82 criteria and from controls was investigated using the Illumina HM450K array. The discovery cohort included 311 patients and 400 controls, and the replication cohort comprised 175 patients and 187 controls. Seventeen independent, top differentially methylated CpG sites (Δβ of ≥0.1) from case–control comparisons were used to calculate the MRS. Genotyping was performed using the Immunochip, and the PRS included 57 non-HLA SLE single-nucleotide variants. Clinical data were collected from patient charts, and serum IFN-α2 was measured using Simoa. Results: Higher MRS was strongly associated with serum IFN-α2 levels (P = 1.04 × 10−14). In both cohorts, higher MRS was associated with DLE, immunologic involvement, and anti-SSA/SSB/RNP/Sm autoantibodies (all P < 0.05), and with higher disease activity in the discovery cohort (P = 1.50 × 10−4). MRS was also elevated in patients with multiple autoantibodies (P < 1.0 × 10−15) and in HLA-DRB1*03:01 carriers (P < 1.0 × 10−3). In contrast, higher PRS was associated with nephritis, anti-dsDNA positivity, and lower prevalence of anti-SSB antibodies (all P < 0.05). No correlation was observed between the MRS and the PRS (P = 0.35). Conclusion: The MRS defines an IFN-high, HLA-DRB1*03:01-linked SLE subset with multiple autoantibodies, partly distinct from PRS-associated nephritis risk, highlighting potentially divergent pathogenic pathways. These findings underscore the value of integrating genetic and epigenetic data to better understand underlying disease mechanisms in SLE.
- Open Access
- 22 May 2026
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (5) , 1-7
Avacopan in a compassionate use programme for severe anti-neutrophil cytoplasmic antibody-associated vasculitis in Sweden
Avacopan (AVAC), an oral selective C5a receptor inhibitor, has been approved for treatment in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Outside randomized controlled studies, real-world data are scarce. The aim of this study was to provide further insight into the clinical experience of AVAC. We analysed data from 16 patients with severe AAV included in an AVAC compassionate use programme. Disease activity was estimated with the Birmingham Vasculitis Activity Score (BVAS). Fatigue was assessed using the Multidimensional Assessment of Fatigue (MAF). Thirteen patients (81%) were diagnosed with granulomatosis with polyangiitis (GPA) and three (19%) with microscopic polyangiitis. The mean age at AVAC initiation was 51 (range 16-74) years. The median [interquartile range (IQR)] BVAS score was 10 (3.25-13.25) at baseline and 0 (0-0) at 6 months (p < 0.0001). All but one reached clinical remission. Prednisolone was tapered from a median (IQR) dose of 25 (20-60) to 2.5 (0-5) mg/day at 6 months (p = 0.0001). Eight patients discontinued prednisolone [median time 2.5 month1 week to 10 months)]. The median (IQR) estimated glomerular filtration rate in patients with renal AAV (n = 10) increased from 50 (13-75) to 58 (15.5-88) mL/min/1.73 m2 at 6 months (p = 0.055). One patient progressed to end-stage kidney disease, while another was able to discontinue haemodialysis. Serious adverse events were seen in five of the 16 patients (31.3%). The MAF score decreased, with a mean difference of 6.65 (p = 0.05) at 6 months. The use of AVAC in a case series with mainly GPA patients led to rapid clinical improvement, reduction of corticosteroid doses, and improvement in fatigue. The findings demonstrate beneficial effects of AVAC as add-on therapy in severe AAV.
- 22 May 2026
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (5) , 1-7
Open AccessAvacopan in a compassionate use programme for severe anti-neutrophil cytoplasmic antibody-associated vasculitis in Sweden
Avacopan (AVAC), an oral selective C5a receptor inhibitor, has been approved for treatment in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Outside randomized controlled studies, real-world data are scarce. The aim of this study was to provide further insight into the clinical experience of AVAC. We analysed data from 16 patients with severe AAV included in an AVAC compassionate use programme. Disease activity was estimated with the Birmingham Vasculitis Activity Score (BVAS). Fatigue was assessed using the Multidimensional Assessment of Fatigue (MAF). Thirteen patients (81%) were diagnosed with granulomatosis with polyangiitis (GPA) and three (19%) with microscopic polyangiitis. The mean age at AVAC initiation was 51 (range 16-74) years. The median [interquartile range (IQR)] BVAS score was 10 (3.25-13.25) at baseline and 0 (0-0) at 6 months (p < 0.0001). All but one reached clinical remission. Prednisolone was tapered from a median (IQR) dose of 25 (20-60) to 2.5 (0-5) mg/day at 6 months (p = 0.0001). Eight patients discontinued prednisolone [median time 2.5 month1 week to 10 months)]. The median (IQR) estimated glomerular filtration rate in patients with renal AAV (n = 10) increased from 50 (13-75) to 58 (15.5-88) mL/min/1.73 m2 at 6 months (p = 0.055). One patient progressed to end-stage kidney disease, while another was able to discontinue haemodialysis. Serious adverse events were seen in five of the 16 patients (31.3%). The MAF score decreased, with a mean difference of 6.65 (p = 0.05) at 6 months. The use of AVAC in a case series with mainly GPA patients led to rapid clinical improvement, reduction of corticosteroid doses, and improvement in fatigue. The findings demonstrate beneficial effects of AVAC as add-on therapy in severe AAV.
- Open Access
- 7 May 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Second delivery rates and recurrence of adverse pregnancy outcomes in women with systemic lupus erythematosus: a nationwide population-based cohort study
Objectives: To assess the rate of a second delivery and the recurrence of adverse pregnancy outcomes (APOs) in women with SLE compared with the general obstetric population. Methods: This nationwide population-based cohort study used Swedish registers to identify women with SLE who had a first singleton liveborn delivery after SLE diagnosis. Up to ten non-SLE comparators were matched on birth year and residence. Second delivery rates were evaluated among women whose first delivery occurred during 2003–2020, with follow-up for second deliveries until the end of 2021. Recurrence of ≥1 APO, preeclampsia and preterm delivery was assessed among women with two deliveries during 2003–2022. Cox proportional hazards models estimated hazard ratios (HRs) for second delivery, and modified Poisson models estimated risk ratios (RRs) for APO recurrence, adjusted for maternal age, education, BMI, smoking, APOs and caesarean section. Results: Second delivery rates were analysed in 543 women with SLE and 17 218 comparators. Over a median follow-up of 2.3 years, incidence rates of second delivery were 156 and 176 per 1000 person-years in women with and without SLE, respectively (adjusted HR 0.89, 95% CI 0.80–0.99). The adjusted HR was 0.78 (0.63–0.96) among women with ≥1 APO in the first pregnancy. Women with SLE had a higher risk of recurrence of APOs, including preeclampsia (RR 1.38), preterm delivery (RR 2.31) and any APO (RR 1.54). Conclusion: Women with SLE have a lower rate of a second delivery and a higher recurrence risk of APOs, highlighting the need for individualized reproductive counselling and close monitoring.
- 7 May 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Open AccessSecond delivery rates and recurrence of adverse pregnancy outcomes in women with systemic lupus erythematosus: a nationwide population-based cohort study
Objectives: To assess the rate of a second delivery and the recurrence of adverse pregnancy outcomes (APOs) in women with SLE compared with the general obstetric population. Methods: This nationwide population-based cohort study used Swedish registers to identify women with SLE who had a first singleton liveborn delivery after SLE diagnosis. Up to ten non-SLE comparators were matched on birth year and residence. Second delivery rates were evaluated among women whose first delivery occurred during 2003–2020, with follow-up for second deliveries until the end of 2021. Recurrence of ≥1 APO, preeclampsia and preterm delivery was assessed among women with two deliveries during 2003–2022. Cox proportional hazards models estimated hazard ratios (HRs) for second delivery, and modified Poisson models estimated risk ratios (RRs) for APO recurrence, adjusted for maternal age, education, BMI, smoking, APOs and caesarean section. Results: Second delivery rates were analysed in 543 women with SLE and 17 218 comparators. Over a median follow-up of 2.3 years, incidence rates of second delivery were 156 and 176 per 1000 person-years in women with and without SLE, respectively (adjusted HR 0.89, 95% CI 0.80–0.99). The adjusted HR was 0.78 (0.63–0.96) among women with ≥1 APO in the first pregnancy. Women with SLE had a higher risk of recurrence of APOs, including preeclampsia (RR 1.38), preterm delivery (RR 2.31) and any APO (RR 1.54). Conclusion: Women with SLE have a lower rate of a second delivery and a higher recurrence risk of APOs, highlighting the need for individualized reproductive counselling and close monitoring.
- Open Access
Methylation Risk Score Identifies an Interferon-Driven SLE Subset Distinct from Polygenic Risk
Objectives: The aetiopathogenesis of SLE encompasses genetic, environmental and epigenetic factors. We investigated associations between an SLE methylation risk score (MRS), HLA-DRB1*03:01, a non-HLA polygenic risk score (PRS) and clinical and immunological phenotypes. Methods: DNA methylation in whole blood from patients fulfilling ≥4 ACR-82 criteria and controls were investigated using the Illumina HM450K array. The discovery cohort included 311 patients and 400 controls, and the replication cohort comprised 175 patients and 187 controls. Seventeen independent, top differentially methylated CpG sites (Δβ of ≥0.1) from case-control comparisons, were used to calculate the MRS. Genotyping was performed using the Immunochip, and the PRS included 57 non-HLA SLE SNVs. Clinical data were collected from patient charts, and serum IFN-α2 was measured using Simoa. Results: Higher MRS was strongly associated with serum IFN-α2 levels (p=1.04×10 −14 ). In both cohorts, higher MRS associated with discoid lupus, immunologic involvement, and anti-SSA/SSB/RNP/Sm autoantibodies (all p-15 ) and in HLA-DRB1*03:01 carriers (p-3 ). In contrast, higher PRS was associated with nephritis, anti-dsDNA positivity, and lower prevalence of anti-SSB antibodies (all p<0.05). No correlation was observed between the MRS and the PRS (p=0.35). Conclusion: The MRS defines an interferon-high, HLA-DRB1*03:01-linked SLE subset with multiple autoantibodies, partly distinct from PRS-associated nephritis risk, highlighting potentially divergent pathogenic pathways. These findings underscore the value of integrating genetic and epigenetic data to better understand underlying disease mechanisms in SLE. Key Messages: Higher MRS, but not PRS, correlated with increased levels of serum IFN-α. The MRS was associated with discoid rash, hematologic disorder, hypocomplementemia, antibodies including anti-SSA and HLA-DRB1*03:01. Higher PRS was linked to nephritis and anti-dsDNA positivity, and did not associate with the MRS.
Open AccessMethylation Risk Score Identifies an Interferon-Driven SLE Subset Distinct from Polygenic Risk
Objectives: The aetiopathogenesis of SLE encompasses genetic, environmental and epigenetic factors. We investigated associations between an SLE methylation risk score (MRS), HLA-DRB1*03:01, a non-HLA polygenic risk score (PRS) and clinical and immunological phenotypes. Methods: DNA methylation in whole blood from patients fulfilling ≥4 ACR-82 criteria and controls were investigated using the Illumina HM450K array. The discovery cohort included 311 patients and 400 controls, and the replication cohort comprised 175 patients and 187 controls. Seventeen independent, top differentially methylated CpG sites (Δβ of ≥0.1) from case-control comparisons, were used to calculate the MRS. Genotyping was performed using the Immunochip, and the PRS included 57 non-HLA SLE SNVs. Clinical data were collected from patient charts, and serum IFN-α2 was measured using Simoa. Results: Higher MRS was strongly associated with serum IFN-α2 levels (p=1.04×10 −14 ). In both cohorts, higher MRS associated with discoid lupus, immunologic involvement, and anti-SSA/SSB/RNP/Sm autoantibodies (all p-15 ) and in HLA-DRB1*03:01 carriers (p-3 ). In contrast, higher PRS was associated with nephritis, anti-dsDNA positivity, and lower prevalence of anti-SSB antibodies (all p<0.05). No correlation was observed between the MRS and the PRS (p=0.35). Conclusion: The MRS defines an interferon-high, HLA-DRB1*03:01-linked SLE subset with multiple autoantibodies, partly distinct from PRS-associated nephritis risk, highlighting potentially divergent pathogenic pathways. These findings underscore the value of integrating genetic and epigenetic data to better understand underlying disease mechanisms in SLE. Key Messages: Higher MRS, but not PRS, correlated with increased levels of serum IFN-α. The MRS was associated with discoid rash, hematologic disorder, hypocomplementemia, antibodies including anti-SSA and HLA-DRB1*03:01. Higher PRS was linked to nephritis and anti-dsDNA positivity, and did not associate with the MRS.
- Open Access
- 1 January 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (1) , e001890
Lectin pathway of complement in SLE: MAP-1 as a marker of haematological manifestations and elevated type I interferon activity
Objective: SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the contribution of the lectin pathway remains unclear. Lectin pathway-dependent complement activation is initiated by pattern-recognition molecules complexed with mannose-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated proteins (MAPs). Here, we combined biochemical and genetic analyses to explore associations between MASP/MAP proteins, SLE manifestations and autoantibody specificities. Methods: Serum concentrations of MASP-3, MAP-1 and MASP-2 were measured using ELISA in Swedish patients with SLE (n=522) and population-based matched controls (n=322). Serum type I interferon activity was measured by a cell-based reporter assay. Associations with SLE manifestations and autoantibodies were explored using logistic regression models. Single-nucleotide genetic variants spanning the MASP1 and MASP2 genes were analysed for associations with MASP/MAP levels and SLE manifestations. Results: Patients with MAP-1 serum concentrations in the highest quartile had significantly higher rates of discoid rash (OR 2.8 (95% CI 1.4 to 5.7)), haematological manifestations (OR 2.1 (95% CI 1.1 to 3.7)) and autoantibodies against Sm, RNP, SSA and SSB (ORs 2.4 (95% CI 1.3 to 4.6) to 3.6 (95% CI 1.7 to 7.7)). Patients in the highest quartiles of MAP-1 and MASP-2 had lower rates of anti-β2GP1 and anti-cardiolipin IgG and IgA anti-phospholipid antibodies (ORs 0.29 (95% CI 0.12 to 0.68) to 0.56 (95% CI 0.31 to 1.0)). Serum MAP-1 levels correlated with type I interferon activity (Spearman’s rho 0.34, p<0.0001), which mediated the associations of MAP-1 with haematological manifestations and Sm/RNP autoantibodies. Significant protein quantitative trait loci for MAP-1 and MASP-2 were identified; however, these did not show consistent associations with SLE or specific SLE manifestations. Conclusions: These results demonstrate a distinct clinical and serological SLE profile associated with components of the lectin pathway. The lectin pathway-regulatory protein MAP-1 displayed the strongest associations and may serve as a marker of SLE manifestations with a type I interferon signature.
- 1 January 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (1) , e001890
Open AccessLectin pathway of complement in SLE: MAP-1 as a marker of haematological manifestations and elevated type I interferon activity
Objective: SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the contribution of the lectin pathway remains unclear. Lectin pathway-dependent complement activation is initiated by pattern-recognition molecules complexed with mannose-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated proteins (MAPs). Here, we combined biochemical and genetic analyses to explore associations between MASP/MAP proteins, SLE manifestations and autoantibody specificities. Methods: Serum concentrations of MASP-3, MAP-1 and MASP-2 were measured using ELISA in Swedish patients with SLE (n=522) and population-based matched controls (n=322). Serum type I interferon activity was measured by a cell-based reporter assay. Associations with SLE manifestations and autoantibodies were explored using logistic regression models. Single-nucleotide genetic variants spanning the MASP1 and MASP2 genes were analysed for associations with MASP/MAP levels and SLE manifestations. Results: Patients with MAP-1 serum concentrations in the highest quartile had significantly higher rates of discoid rash (OR 2.8 (95% CI 1.4 to 5.7)), haematological manifestations (OR 2.1 (95% CI 1.1 to 3.7)) and autoantibodies against Sm, RNP, SSA and SSB (ORs 2.4 (95% CI 1.3 to 4.6) to 3.6 (95% CI 1.7 to 7.7)). Patients in the highest quartiles of MAP-1 and MASP-2 had lower rates of anti-β2GP1 and anti-cardiolipin IgG and IgA anti-phospholipid antibodies (ORs 0.29 (95% CI 0.12 to 0.68) to 0.56 (95% CI 0.31 to 1.0)). Serum MAP-1 levels correlated with type I interferon activity (Spearman’s rho 0.34, p<0.0001), which mediated the associations of MAP-1 with haematological manifestations and Sm/RNP autoantibodies. Significant protein quantitative trait loci for MAP-1 and MASP-2 were identified; however, these did not show consistent associations with SLE or specific SLE manifestations. Conclusions: These results demonstrate a distinct clinical and serological SLE profile associated with components of the lectin pathway. The lectin pathway-regulatory protein MAP-1 displayed the strongest associations and may serve as a marker of SLE manifestations with a type I interferon signature.
- Top Cited Papers
- 18 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 390 (6779) , eadx2678
A human pan-disease blood atlas of the circulating proteome
The human blood proteome provides a holistic readout of health states through the assessment of thousands of circulating proteins. In this study, we present a pan-disease resource to enable the study of diverse disease phenotypes within a harmonized proteomics dataset. By profiling protein concentrations across 59 diseases and healthy cohorts, we identified proteins associated with age, sex, and body mass index, as well as disease-specific signatures. This study highlights shared and distinct protein patterns across conditions, demonstrating the power of a unified proteomics approach to uncover biological insights. The dataset, covering 8262 individuals and up to 5416 proteins, serves as an online resource for exploring disease-specific protein profiles and advancing precision medicine research.
- 18 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 390 (6779) , eadx2678
Top Cited PapersA human pan-disease blood atlas of the circulating proteome
The human blood proteome provides a holistic readout of health states through the assessment of thousands of circulating proteins. In this study, we present a pan-disease resource to enable the study of diverse disease phenotypes within a harmonized proteomics dataset. By profiling protein concentrations across 59 diseases and healthy cohorts, we identified proteins associated with age, sex, and body mass index, as well as disease-specific signatures. This study highlights shared and distinct protein patterns across conditions, demonstrating the power of a unified proteomics approach to uncover biological insights. The dataset, covering 8262 individuals and up to 5416 proteins, serves as an online resource for exploring disease-specific protein profiles and advancing precision medicine research.
- Open Access
- 9 December 2025
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (3) , 184-190
Sensitive detection of plasma interferon regulatory factor-5 (IRF5) by solid-phase proximity ligation assay validates IRF5 high and low subgroups in patients with systemic lupus erythematosus
Interferon regulatory factor 5 (IRF5) plays a central role in interferon-mediated inflammation and is implicated in autoimmune diseases, including systemic lupus erythematosus (SLE). Detecting IRF5 in plasma is challenging due to its low circulating levels, highlighting the need for a highly sensitive and quantitative assay. This study aimed to develop such an assay, validate the existence of previously identified IRF5 high and low subgroups in SLE, and support the potential of IRF5 as a biomarker in precision medicine. We established a solid-phase proximity ligation assay (SP-PLA) for IRF5 detection using a commercially available polyclonal antibody, which was benchmarked against two in-house recombinant antibodies. A linear calibration curve was generated using recombinant IRF5 protein (range 0.01-100 pg/µL), with a limit of detection between 0.01 and 0.05 pg/µL. EDTA-plasma samples from three SLE subgroups (n = 25 per group) were analysed. IRF5 was detectable in all SLE plasma samples using SP-PLA (mean 0.63 pg/µL; sd 1.92 pg/µL; maximum 13.54 pg/µL). The IRF5 high SLE subgroup showed significantly higher IRF5 plasma levels than the IRF5 low SLE subgroup (Dunn's post-hoc test, adjusted p < 0.05). The SP-PLA enabled sensitive and specific detection of low-level IRF5 in plasma and confirmed the presence of IRF5 high and low subgroups in SLE using a quantitative method. These findings support the potential of IRF5 as a biomarker, but validation in independent cohorts is required. The assay may facilitate patient stratification in future research and precision medicine approaches targeting the interferon pathway.
- 9 December 2025
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (3) , 184-190
Open AccessSensitive detection of plasma interferon regulatory factor-5 (IRF5) by solid-phase proximity ligation assay validates IRF5 high and low subgroups in patients with systemic lupus erythematosus
Interferon regulatory factor 5 (IRF5) plays a central role in interferon-mediated inflammation and is implicated in autoimmune diseases, including systemic lupus erythematosus (SLE). Detecting IRF5 in plasma is challenging due to its low circulating levels, highlighting the need for a highly sensitive and quantitative assay. This study aimed to develop such an assay, validate the existence of previously identified IRF5 high and low subgroups in SLE, and support the potential of IRF5 as a biomarker in precision medicine. We established a solid-phase proximity ligation assay (SP-PLA) for IRF5 detection using a commercially available polyclonal antibody, which was benchmarked against two in-house recombinant antibodies. A linear calibration curve was generated using recombinant IRF5 protein (range 0.01-100 pg/µL), with a limit of detection between 0.01 and 0.05 pg/µL. EDTA-plasma samples from three SLE subgroups (n = 25 per group) were analysed. IRF5 was detectable in all SLE plasma samples using SP-PLA (mean 0.63 pg/µL; sd 1.92 pg/µL; maximum 13.54 pg/µL). The IRF5 high SLE subgroup showed significantly higher IRF5 plasma levels than the IRF5 low SLE subgroup (Dunn's post-hoc test, adjusted p < 0.05). The SP-PLA enabled sensitive and specific detection of low-level IRF5 in plasma and confirmed the presence of IRF5 high and low subgroups in SLE using a quantitative method. These findings support the potential of IRF5 as a biomarker, but validation in independent cohorts is required. The assay may facilitate patient stratification in future research and precision medicine approaches targeting the interferon pathway.